Skip to main content

Advertisement

SpringerLink
Log in

Lymphoblastic lymphoma in adults

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Understanding of the pathogenesis and biology of precursor T-cell and B-cell neoplasms has advanced significantly with the description of gene expression profiling studies, especially in T-cell disease. These studies have demonstrated leukemic arrest at various stages of thymocyte maturation, characterized by gene expression signatures with prognostic significance. Optimal treatment strategies for adult lymphoblastic lymphoma are uncertain, although current evidence supports the use of regimens similar to those used in acute lymphoblastic leukemia, with intensive induction therapy, central nervous system prophylaxis, and prolonged consolidation maintenance therapy. Current studies do not demonstrate a benefit from stem cell transplantation in first remission, although this approach is probably beneficial in relapsed disease. Identification of new therapeutic targets by further molecular studies is required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. The Non-Hodgkin’s Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997, 89:3909–3918.

    Google Scholar 

  2. Rosen PJ, Feinstein DI, Pattengale PK, et al.: Convoluted lymphocytic lymphoma in adults: a clinicopathological entity. Ann Intern Med 1978, 89:319–324.

    PubMed  CAS  Google Scholar 

  3. Nathwani BN, Diamond LW, Winberg CD, et al.: Lymphoblastic lymphoma: a clinicopathologic study of 95 patients. Cancer 1978, 48:2347–2357.

    Article  Google Scholar 

  4. Li S, Juco J, Mann KP, Holden JT: Flow cytometry in the differential diagnosis of lymphocyte-rich thymoma from precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. Am J Clin Pathol 2004, 121:268–274.

    Article  PubMed  Google Scholar 

  5. Sheibani K, Nathwani BN, Winberg CD, et al.: Antigenically defined subgroups of lymphoblastic lymphoma: relationship to clinical presentation and biologic behavior. Cancer 1987, 60:183–190.

    Article  PubMed  CAS  Google Scholar 

  6. Link MP, Stewart SJ, Warnke RA, et al.: Discordance between surface and cytoplasmic expression of the Leu-4 (T3) antigen in thymocytes and in blast cells from childhood lymphoblastic malignancies. J Clin Invest 1985, 76:248–253.

    PubMed  CAS  Google Scholar 

  7. Kiyokawa N, Sekino T, Matsui T, et al.: Diagnostic importance of CD179a/b as markers of precursor B-cell lymphoblastic lymphoma. Mod Pathol 2004, 17:423–429.

    Article  PubMed  Google Scholar 

  8. Pilozzi E, Muller-Hermelink HK, Falini B, et al.: Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol 1999, 188:267–270.

    Article  PubMed  CAS  Google Scholar 

  9. Okuda T, Fisher R, Downing JR: Molecular diagnostics in pediatric acute lymphoblastic leukemia. Mol Diagn 1996, 1:139–151.

    Article  PubMed  CAS  Google Scholar 

  10. Ferrando AA, Neuberg DS, Staunton J, et al.: Gene expression signatures define novel oncogenic pathways in acute lymphoblastic leukemia. Cancer Cell 2002, 75–87.

  11. Cave H, Suciu S, Preudhomme C, et al.: Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood 2004, 103:442–450.

    Article  PubMed  CAS  Google Scholar 

  12. Colgan JP, Andersen J, Habermann TM, et al.: Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin’s lymphoma. Leuk Lymphoma 1994, 15:291–296.

    PubMed  CAS  Google Scholar 

  13. Kaiser U, Uebelacker I, Havemann K: Non-Hodgkin’s lymphoma protocols in the treatment of patients with Burkitt’s lymphoma and lymphoblastic lymphoma: a report on 58 patients. Leuk Lymphoma 1999, 36:101–108.

    Article  PubMed  CAS  Google Scholar 

  14. Jost LM, Jacky E, Dommann-Scherrer C, et al.: Short-term weekly chemotherapy followed by high dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt’s lymphomas in adult patients. Ann Oncol 1995, 6:445–451.

    PubMed  CAS  Google Scholar 

  15. Le Gouill S, Lepretre S, Briere J, et al.: Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials. Leukemia 2003, 17:2220–2224.

    Article  PubMed  CAS  Google Scholar 

  16. van Imhoff GW, van der Holt B, MacKenzie MA, et al.: Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 2005, 19:945–952. An important "negative" study demonstrating that the use of autologous stem cell transplantation does not substitute for intensive induction chemotherapy, CNS prophylaxis, and consolidation/maintenance therapy as used in acute lymphoblastic leukemia.

    Article  PubMed  CAS  Google Scholar 

  17. Wollner N, Burchenal JH, Lieberman PH, et al.: Non-Hodgkin’s lymphoma in children. A progress report on the original patients treated with the LSA2-L2 protocol. Cancer 1979, 44:19990–1999.

    Article  Google Scholar 

  18. Mora J, Filippa DA, Qin J, Wollner N: Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial Sloan-Kettering Cancer Center. Cancer 2003, 98:1283–1291.

    Article  PubMed  Google Scholar 

  19. Anderson JR, Wilson JF, Jenkin DT, et al.: Childhood non-Hodgkin’s lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 1983, 308:559–565.

    Article  PubMed  CAS  Google Scholar 

  20. Coleman CN, Cohen JR, Burke JS, Rosenberg SA: Lymphoblastic lymphoma in adults: results of a pilot protocol. Blood 1981, 57:679–684.

    PubMed  CAS  Google Scholar 

  21. Coleman CN, Picozzi VJ Jr, Cox RS, et al.: Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986, 4:1628–1637.

    PubMed  CAS  Google Scholar 

  22. Slater DE, Mertelsmann R, Koziner B, et al.: Lymphoblastic lymphoma in adults. J Clin Oncol 1986, 4:57–67.

    PubMed  CAS  Google Scholar 

  23. Bernasconi C, Brusamolino E, Lazzarino M, et al.: Lymphoblastic lymphoma in adult patients: clinicopathological features and response to intensive multiagent chemotherapy analogous to that used in acute lymphoblastic leukemia. Ann Oncol 1990, 1:141–146.

    PubMed  CAS  Google Scholar 

  24. Daenen S, van Imhoff GW, Haaxma-Reiche H, et al.: Acute lymphoblastic leukemia: single center experience with modified chemotherapy [abstract]. Blood 1995, 86:745a.

    Google Scholar 

  25. Zinzani PL, Bendandi M, Visani G, et al.: Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leuk Lymphoma 1996, 23:577–582.

    PubMed  CAS  Google Scholar 

  26. Bouabdallah R, Xerri L, Bardou VJ, et al.: Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Ann Oncol 1998, 9:619–625.

    Article  PubMed  CAS  Google Scholar 

  27. Hoelzer D, Gökbuget N, Digel W, et al.: Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002, 99:4379–4385.

    Article  PubMed  CAS  Google Scholar 

  28. Thomas DA, O’Brian S, Cortes J, et al.: Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004, 104:1624–1630.

    Article  PubMed  CAS  Google Scholar 

  29. Dabaja BS, Ha CS, Thomas DA, et al.: The role of local radiation therapy for mediastinal disease in adults with Tcell lymphoblastic lymphoma. Cancer 2002, 94:2738–2744.

    Article  PubMed  Google Scholar 

  30. Milpied N, Ifrah N, Kuentz M, et al.: Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 1989, 73:82–87.

    PubMed  CAS  Google Scholar 

  31. Verdonck LF, Dekker AW, de Gast GC, et al.: Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission. J Clin Oncol 1992, 10:644–646.

    PubMed  CAS  Google Scholar 

  32. Baro J, Richard C, Sierra J, et al.: Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional dose chemotherapy. Bone Marrow Transplant 1992, 10:33–38.

    PubMed  CAS  Google Scholar 

  33. Sweetenham JW, Liberti G, Pearce R, et al.: High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. J Clin Oncol 1994, 12:1358–1365.

    PubMed  CAS  Google Scholar 

  34. Sweetenham JW, Santini G, Qian W, et al.: High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 2001, 19:2927–2936.

    PubMed  CAS  Google Scholar 

  35. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al.; European Bone Marrow Transplantation (EBMT) Lymphoma Registry: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003, 31:667–678.

    Article  PubMed  CAS  Google Scholar 

  36. Levine JE, Harris RE, Loberiza FR, et al.: A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003, 101:2476–2482.

    Article  PubMed  CAS  Google Scholar 

  37. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993, 329:987–994.

    Article  Google Scholar 

  38. Kostakoglu L, Coleman M, Leonard JP, et al.: PET predicts prognosis after one cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002, 43:1018–1027.

    PubMed  Google Scholar 

  39. Haioun C, Itti E, Rahmouni A, et al.: [18F] fiuoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early tool for predicting patient outcome. Blood 2005, 106:1376–1381.

    Article  PubMed  CAS  Google Scholar 

  40. Czuczman MS, Dodge RK, Stewart CC, et al.: Value of immunophenotyping in intensively treated adult acute lymphoblastic leukemia. Cancer and Leukemia Group B study 8364. Blood 1999, 93:3931–3939.

    PubMed  CAS  Google Scholar 

  41. Ferrando AA, Armstrong SA, Neuberg DS, et al.: Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: Dominance of HOX dysregulation. Blood 2003, 102:262–268.

    Article  PubMed  CAS  Google Scholar 

  42. Kurtzberg J, Keating M, Moore JO, et al.: 2-amino-9-B-Darabinosyl-6-methoxy-9H-guanine (GW506U; compound 506U) is highly active in patients with T-cell malignancies: results of a phase I trial in pediatric and adult patients with refractory hematological malignancies [abstract]. Blood 1996, 88:2666a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology & Oncology/R35, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195, Cleveland, OH, USA

    John W. Sweetenham MD

Authors
  1. John W. Sweetenham MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John W. Sweetenham MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sweetenham, J.W. Lymphoblastic lymphoma in adults. Curr Hematol Malig Rep 1, 241–247 (2006). https://doi.org/10.1007/s11899-006-0005-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-006-0005-8

Keywords

Search

Navigation